Gene-Specific Template (Updated 9-28-21): Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 36: | Line 36: | ||
EXAMPLE: | EXAMPLE: | ||
* ''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016). | *''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016). | ||
* Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519). | *Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519). | ||
* Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21). | *Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21). | ||
==Clinical Cancer Associations (Somatic)== | ==Clinical Cancer Associations (Somatic)== | ||
(''Instruction: include references and links to related internal CCGA pages'') | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Tumor Type''' | |'''Tumor Type''' | ||
| Line 48: | Line 49: | ||
|'''Therapeutic Significance (Yes, No or Unknown)''' | |'''Therapeutic Significance (Yes, No or Unknown)''' | ||
|- | |- | ||
|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link to internal page | |EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link this name to internal page using link icon above) | ||
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation | |EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation | ||
| | | | ||
| Line 68: | Line 69: | ||
==Clinical Cancer Associations (Germline)== | ==Clinical Cancer Associations (Germline)== | ||
(''Instruction: include references and links to related internal CCGA pages'') | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Tumor Type''' | |'''Tumor Type''' | ||
| Line 75: | Line 77: | ||
|'''Therapeutic Significance (Yes, No or Unknown)''' | |'''Therapeutic Significance (Yes, No or Unknown)''' | ||
|- | |- | ||
|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link to internal page | |EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link this name to internal page using link icon above) | ||
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, | |EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, | ||
| | | | ||
| Line 87: | Line 89: | ||
| | | | ||
|- | |- | ||
|} | |} | ||